Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib in pretreated metastatic NSCLC with MET amplification or ROS1 translocation (METROS)
2014-001263-12Phase 2Active
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of crizotinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Fondazione Ricerca Traslazionale. Primary endpoint: Co-primary endpoints. Started Jun 2014; status: active.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-001263-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001263-12.